Literature DB >> 7799003

Usefulness of movement time in the assessment of Parkinson's disease.

M Zappia1, R Montesanti, R Colao, A Quattrone.   

Abstract

Reaction time (RT) and movement time (MT) are reported to be delayed in Parkinson's disease (PD), but their clinical utility and relationship with clinical findings is still uncertain. We investigated RT and MT in 22 PD patients at baseline conditions and following acute oral trials of levodopa and biperiden, an anticholinergic drug. At baseline conditions, RT and MT of PD patients were abnormally delayed compared with those of 16 normal control subjects. Both RT and MT were longer in more severely affected patients compared with the mild PD patients; in the mild PD patients with asymmetrical signs both responses were longer on the more affected side. Bradykinesia was the clinical symptom that best correlated with the objective measurements, with a stronger correlation for MT than for RT. The oral administration of levodopa significantly improved both the responses, whereas biperiden was ineffective. The magnitude of RT and MT improvement after levodopa differed; MT improvement was related to PD severity, whereas RT improvement was not. These results suggest that MT, rather than RT, is an objective, simple, and reliable tool to evaluate bradykinesia and its levodopa-induced modifications in PD.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7799003     DOI: 10.1007/bf00873517

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  57 in total

1.  Response to a standard oral levodopa test in parkinsonian patients with and without motor fluctuations.

Authors:  M Contin; R Riva; P Martinelli; G Procaccianti; P Cortelli; P Avoni; A Baruzzi
Journal:  Clin Neuropharmacol       Date:  1990-02       Impact factor: 1.592

2.  Objective measurement of motor disability in Parkinson's disease.

Authors:  G Steg; P E Ingvarsson; B Johnels; M Valls; M Thorselius
Journal:  Acta Neurol Scand Suppl       Date:  1989

3.  Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients.

Authors:  S T Gancher; J G Nutt; W R Woodward
Journal:  Neurology       Date:  1987-06       Impact factor: 9.910

4.  Possible involvement of attention processes in Parkinson's disease.

Authors:  F Girotti; M P Grassi; F Carella; P Soliveri; M Musicco; E Lamperti; T Caraceni
Journal:  Adv Neurol       Date:  1987

5.  Reaction time in Parkinson's disease.

Authors:  E V Evarts; H Teräväinen; D B Calne
Journal:  Brain       Date:  1981-03       Impact factor: 13.501

6.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

7.  Human ballistic arm abduction movements: effects of L-dopa treatment in Parkinson's disease.

Authors:  A Baroni; F Benvenuti; L Fantini; T Pantaleo; F Urbani
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

8.  Patients with Parkinson's disease can employ a predictive motor strategy.

Authors:  B L Day; J P Dick; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-12       Impact factor: 10.154

9.  Reaction time and vigilance in Parkinson's disease. Possible role of altered norepinephrine metabolism.

Authors:  Y Stern; R Mayeux; L Côté
Journal:  Arch Neurol       Date:  1984-10

Review 10.  Bradykinesia in Parkinson's disease: disorders of onset and execution of fast movement.

Authors:  N Yanagisawa; S Fujimoto; F Tamaru
Journal:  Eur Neurol       Date:  1989       Impact factor: 1.710

View more
  4 in total

Review 1.  The role of the long-duration response to levodopa in Parkinson's disease.

Authors:  Mario Zappia; Alessandra Nicoletti
Journal:  J Neurol       Date:  2010-11       Impact factor: 4.849

Review 2.  Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection.

Authors:  Giovanni Abbruzzese; Paolo Barone; Ubaldo Bonuccelli; Leonardo Lopiano; Angelo Antonini
Journal:  Funct Neurol       Date:  2012 Jul-Sep

3.  Dopaminergic influences on risk preferences of Parkinson's disease patients.

Authors:  Shunsuke Kobayashi; Kohei Asano; Nozomu Matsuda; Yoshikazu Ugawa
Journal:  Cogn Affect Behav Neurosci       Date:  2019-02       Impact factor: 3.282

4.  Structural MRI substrate of long-duration response to levodopa in Parkinson's disease: an exploratory study.

Authors:  Giulia Donzuso; Giorgia Sciacca; Cristina Rascunà; Calogero E Cicero; Giovanni Mostile; Alessandra Nicoletti; Mario Zappia
Journal:  J Neurol       Date:  2021-04-17       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.